AM-710

About Aion Medicines

Aion Medicines is a private, preclinical-stage biotech tackling the chronic disease epidemic through an ultra-long-acting drug delivery platform. Its primary asset, AM-710, is a small-molecule GLP-1R agonist in development for type 2 diabetes and obesity with potential dosing intervals of three to six months or longer, aiming for a best-in-class profile. The company is led by a team with deep drug development experience and is supported by a high-profile scientific advisory board. Aion operates in a pre-revenue stage, targeting massive markets with significant unmet needs in patient adherence.

Therapeutic Areas